President and Chief Executive Officer Mpex Pharmaceuticals, Inc.
Daniel D. Burgess has served as a member of our board of directors since July 2004. Since June 2011, Mr. Burgess has been President and Chief Executive Officer of Rempex Pharmaceuticals, Inc., a private biopharmaceutical company. From May 2007 Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, Inc., which was acquired by Aptalis Pharma Inc. in 2011. Previously, Mr. Burgess was Chief Operating Officer and Chief Financial Officer of Harbor BioSciences, Inc., formerly Hollis-Eden Pharmaceuticals, Inc. Prior to Hollis-Eden, Mr. Burgess spent ten years with Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Limited) where he held a variety of executive level positions with responsibility for overall finance for the company as well as a number of different operating units. Mr. Burgess holds a B.A. in economics from Stanford University and an M.B.A. from Harvard Business School.